Cancer of Pancreas Clinical Trial
— PIOPPOOfficial title:
Phase II Clinical Study on Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative Treatment With Chemotherapy and Carbon Ions Radiation Therapy (Hadrontherapy)
Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | February 8, 2023 |
Est. primary completion date | February 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - histologic/cytologic diagnosis of exocrine pancreas tumour - resectable or borderline resectable exocrine pancreatic tumour (according to operability criteria) - no metastasis from US, CT, PET, MRI or laparotomy - Karnofsky index >= 70 - stomach and duodenum not infiltrated by tumour - given informed consent to study procedures - Hb > 9 g/dL, N> 1500, PLT> 100000 - creatininemia < 1.5 mg/dL; bilirubinemia < 1.5 times upper normal values; albumin > 3 g/dL - DPD normal activity - contraception required and breast feeding not permitted Exclusion Criteria: - non resectable, locally advanced tumours - insular cells tumour - comorbidities excluding abdominal surgery and/or chemo- radiation therapy - known metastasis - DPD low activity - inability to attend study procedures and follow ups - pregnancy - previous diagnosis of other tumour with more disadvantageous prognosis then the study object - metallic biliary stent - metallic prothesis or any other condition to prevent from target volume individuation and dose calculation - clinical condition preventing from radiation therapy (i.e. infections in the irradiation area) - medical and/or psychical condition preventing from radiation therapy - past radiation therapy on abdomen. |
Country | Name | City | State |
---|---|---|---|
Italy | CNAO | Pavia |
Lead Sponsor | Collaborator |
---|---|
CNAO National Center of Oncological Hadrontherapy | Foundation IRCCS San Matteo Hospital |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival | The local progression free survival is measured | The local progression free survival will be assessed at 1-year | |
Secondary | overall survival | the overall survival of enrolled patients is considered | The overall survival of enrolled patients will be assessed at 2-years | |
Secondary | resectability rate R0 stratified (operable vs not operable) | how many surgeries completed according to the procedures and with histopathological margins free from the disease/enrolled patients | time of surgery (4-6 weeks after radiotherapy) | |
Secondary | Incidence of acute, medium term and late toxicity according to CTCAE v 4.0 grading toxicity | Incidence of acute, medium term and late toxicity according to CTCAE v 4.0 grading toxicity | The incidence of acute and medium term toxicity will be assessed up to 90 and 180 post-operative days respectively. The incidence of late toxicity will be assessed through study completion, an average of 1 year. | |
Secondary | intra and perioperatory complications | intra and perioperatory complications | The incidence of intra- and perioperatory complications will be assessed up to 30 post-operative days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02902484 -
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04008537 -
Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Not yet recruiting |
NCT03659292 -
Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy
|
N/A | |
Completed |
NCT03150615 -
Enteral Nutrition After Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT02682394 -
Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
|
N/A | |
Recruiting |
NCT05566743 -
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
|
Phase 2 | |
Not yet recruiting |
NCT04049461 -
Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
|
||
Recruiting |
NCT04164602 -
The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
|
||
Active, not recruiting |
NCT04128332 -
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
|
N/A | |
Recruiting |
NCT03536793 -
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
|
||
Recruiting |
NCT02311439 -
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
|
Phase 2/Phase 3 | |
Completed |
NCT02296736 -
The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
|
||
Withdrawn |
NCT04123574 -
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT03278015 -
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT02905578 -
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
|
Phase 2 | |
Completed |
NCT01446458 -
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT04677244 -
Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT06148298 -
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
|